BiotechTube
Evia Bio

Evia Bio

Boston, United States· Est.
eviabio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Evia Bio is a private, pre-revenue biotech tools and services company founded in 2020, specializing in non-DMSO cryopreservation technology for cell therapies. Its core platform, driven by AI and the expertise of founder Dr. Allison Hubel, aims to solve critical bottlenecks in cell therapy manufacturing and storage by replacing toxic preservatives. The company operates through a B2B model, providing products, protocol development, and training services to cell therapy developers, positioning itself as an enabler for the broader oncology and immunology therapeutic sectors.

OncologyImmunology

Technology Platform

AI-driven formulation of non-toxic, organic cryoprotectant solutions for cell therapy preservation, aiming to replace the standard DMSO.

Opportunities

The rapid growth of the cell therapy market creates a direct and expanding need for improved cryopreservation solutions.
Increasing regulatory and clinical scrutiny on DMSO toxicity provides a compelling entry point for Evia Bio's safer, potentially more effective alternatives.

Risk Factors

The company must overcome the entrenched use of DMSO and prove clinical superiority.
It faces potential competition from large, well-capitalized life science tools companies and is dependent on the success and pace of the broader cell therapy industry.

Competitive Landscape

Evia Bio competes against the entrenched standard of DMSO-based solutions offered by many media suppliers. Direct competitors in non-DMSO cryopreservation are emerging but limited. Larger strategic competitors include life science tools giants like Thermo Fisher Scientific and Lonza, which have broad cell therapy portfolios and could develop similar technologies.

More companies in Digital Health & Biotech SaaS →More companies in United States →